Clopidogrel - historical and modern base of antiplatelet therapy in acute coronary syndrome
- Авторлар: Taratukhin E.O.1
-
Мекемелер:
- Pirogov Russian National Research Medical University
- Шығарылым: № 6 (2017)
- Беттер: 76-80
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/279087
- ID: 279087
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The article presents a recent insight on antiplatelet therapy in acute coronary syndrome, emphasizing clopidogrel as the most well known medication with the longest experience of usage. The data provided, from the latest European Guidelines, as some new information of translational and clinical trials published current year. A complexity and ambiguity is shown of the platelet part of hemostasis, especially, based on the data from new platelet reactivity trials. Routes are sketched of the choice of one or other medication, depended upon evidence and exact clinical situation.
Негізгі сөздер
Толық мәтін
Авторлар туралы
Evgeny Taratukhin
Pirogov Russian National Research Medical University
Email: cardio03@yandex.ru
MD, PhD, M.A., Associate Professor at the Department of Internal Medicine
Әдебиет тізімі
- Gordeev I.G., Taratukhin E.O., Shaydyuk O. Yu. Clinical Physiology of Hemostasis. Moscow: Silitsea, 2013; 128p. (Russian: Гордеев И.Г., Таратухин Е.О., Шайдюк О.Ю. Клиническая физиология гемостаза. Москва: Силицея, 2013, 128 с.)
- WHO. WHO Model List of Essential Medicines. World Health Organization, 2017, 58p.
- Patrono C. Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. European Heart Journal, 2004; 25(2):166-81
- Li C. Z., Zhang L., Wang H. R., et al. Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - A multicenter study. International Journal of Cardiology, 2017; 240:360-6
- Valgimigli M., Bueno H., Byrne R. A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2017
- Roffi M., Patrono C., Collet J. P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016; 37(3):267-315
- Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017
- Anastasius M., Lau J. K., Hyun K., et al. The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology, 2017; 240:30-6
- Carrabba N., Bellandi B., Parodi G., et al. APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. International Journal of Cardiology, 2017; 244:13-6
- Fanaroff A. C., Hasselblad V., Roe M. T., et al. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017; 241:87-96
- Lowenstern A., Storey R. F., Neely M., et al. Platelet-related biomarkers and their response to inhibition with aspirin and p2y(12)-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017; 44(2): 145-53
- Podda G. M., Grossi E., Palmerini T., et al. Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes. International Journal of Cardiology, 2017; 240: 60-5
- So D. Y. F., Bagai A., Tran U., et al. P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists. Current Opinion in Cardiology, 2017; 32(5): 617-26
- Xanthopoulou I., Davlouros P., Deftereos S., et al. Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the G Ree kAnt i P lat Ele t Registry. Cardiovascular Therapeutics, 2017; 35(4) :12270
Қосымша файлдар
